Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial

Phase I/II trial investigators reported positive early experience with Clearmind Medicine’s non-hallucinogenic MEAI compound for Alcohol Use Disorder. While the article is encouraging, the results are early-stage (Phase I/II), suggesting limited near-term implications until more definitive efficacy and safety data emerge.

Analysis

Phase I/II trial investigators reported positive early experience with Clearmind Medicine’s non-hallucinogenic MEAI compound for Alcohol Use Disorder. While the article is encouraging, the results are early-stage (Phase I/II), suggesting limited near-term implications until more definitive efficacy and safety data emerge.